Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan Eyes Legal System to Ensure Generic Supplies in New Industry Vision, Key Official Says It’s Difficult with Companies’ Own Efforts Alone
It is difficult to ensure the stable supply of generics by relying solely on manufacturers’ own efforts as the utilization rate of these products has grown sharply over the last eight years, says a senior official who spearheaded the formulation…
To read the full story
Related Article
- Japan Unveils New Pharma Industry Vision, 1st Update in 8 Years
September 14, 2021
- New Pharma Industry Vision to Set Out Roles of Wholesalers: MHLW Director
July 16, 2021
- New Industry Vision to Reaffirm Pharmaceuticals as Growth Industry: MHLW Director
April 30, 2021
- Japan to Wade Deeper into Generic Industry Revamp in New Pharma Vision, Due Out Summer
March 29, 2021
- MHLW Presents Views on “Pharma Industry Vision 2021” to LDP’s Project Team
March 8, 2021
- LDP to Set Up Project Team to Strengthen Pharma Sector, Eyes Proposal in May
February 22, 2021
- MHLW Eyes 1st Revision of Drug Industry Vision in 8 Years as Off-Year Re-Pricing Takes Shape: Official
January 19, 2021
REGULATORY
- War-Linked Supply Concerns Rise to 43 Cases, Focus Shifts to Solvents, Packaging
April 24, 2026
- JPMA Pushes for “Freeze” on On-Patent Drug Price Cuts at LDP Meeting
April 23, 2026
- MHLW to Exclude High School-Age and Younger from OTC-Like Drug Charge: Official
April 23, 2026
- Japan, Singapore to Share GMP Inspection Results under Cooperation Pact
April 23, 2026
- MHLW Orders Label Revisions for Remicade, Enbrel, Bavencio, and More Drugs
April 22, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…